Memorial Sloan Kettering Cancer Center’s Caribou Biosciences CRBU Stock Holding History

Memorial Sloan Kettering Cancer Center’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-544,196	Closed	-$2.31M	–	4
2023 Q2	$2.31M	Hold	544,196	–	–	7.3%	3
2023 Q1	$2.89M	Hold	544,196	–	–	8.86%	3
2022 Q4	$3.42M	Hold	544,196	–	–	11.27%	3
2022 Q3	$5.74M	Sell	544,196 -65,000	-11%	-$606K	19.52%	2
2022 Q2	$3.31M	Sell	609,196 -65,000	-10%	-$497K	10.93%	2
2022 Q1	$6.19M	Hold	674,196	–	–	7.17%	3
2021 Q4	$10.2M	Hold	674,196	–	–	6.39%	3
2021 Q3	$16.1M	Buy	+674,196	New	+$16.5M	10.03%	3

Other funds holding CRBU

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

RCMU

Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Memorial Sloan Kettering Cancer Center's CRBU Position: Q3 2023 in Review

Memorial Sloan Kettering Cancer Center sold out of Caribou Biosciences (CRBU) in Q3 2023, closing a stake of 544,196 shares — an estimated $2.31M sold.

Memorial Sloan Kettering Cancer Center first reported a position in CRBU in Q3 2021 and held it in 8 quarters. The position peaked at $16.1M in Q3 2021. 126 funds tracked by Wall St. Rank hold CRBU as of Q3 2023.

Memorial Sloan Kettering Cancer Center reported no remaining Caribou Biosciences position as of Q3 2023 after selling out during the quarter.
Memorial Sloan Kettering Cancer Center sold 544,196 Caribou Biosciences shares in Q3 2023, an estimated $2.31M.
Memorial Sloan Kettering Cancer Center first reported a position in Caribou Biosciences in Q3 2021 and held it in 8 quarters.
Memorial Sloan Kettering Cancer Center's Caribou Biosciences position peaked at $16.1M in Q3 2021.
126 funds tracked by Wall St. Rank held Caribou Biosciences as of Q3 2023.

Based on Memorial Sloan Kettering Cancer Center's 13F filing for Q3 2023, filed 14 Nov 2023.